FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225510445> ?p ?o ?g. }

• W4225510445 abstract "Nucleos(t)ide analogues entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are recommended as first-line monotherapies for chronic hepatitis B (CHB). Multiple HBV genotypes/subgenotypes have been described, but their impact on treatment response remains largely elusive. We investigated the effectiveness of ETV/TDF on HBV/D-subgenotypes, D1/D2/D3/D5, studied the structural/functional differences in subgenotype-specific reverse transcriptase (RT) domains of viral polymerase, and identified novel molecules with robust inhibitory activity on various D-subgenotypes. Transfection of Huh7 cells with full-length D1/D2/D3/D5 and in vitro TDF/ETV susceptibility assays demonstrated that D1/D2 had greater susceptibility to TDF/ETV while D3/D5 exhibited poorer response. Additionally, HBV load was substantially reduced in TDF-treated CHB patients carrying D1/D2 but minimally reduced in D3/D5-infected patients. Comparison of RT sequences of D-subgenotypes led to identification of unique subgenotype-specific residues, and molecular modeling/docking/simulation studies depicted differential bindings of TDF/ETV to the active site of their respective RTs. Replacement of signature residues in D3/D5 HBV clones with corresponding amino acids seen in D1/D2 improved their susceptibility to TDF/ETV. Using high throughput virtual screening, we identified N(9)-[3-fluoro-2-(phosphonomethoxy)propyl] (FPMP) derivatives of purine bases, including N6-substituted (S)-FPMP derivative of 2,6-diaminopurine (DAP) (OB-123-VK), as potential binders of RT of different D-subgenotypes. We synthesized (S)-FPMPG prodrugs (FK-381-FEE/FK-381-SEE/FK-382) and tested their effectiveness along with OB-123-VK. Both OB-123-VK and FK-381-FEE exerted similar antiviral activities against all D-subgenotypes, although FK-381-FEE was more potent. Our study highlighted the natural variation in therapeutic response of D1/D2/D3/D5 and emphasized the need for HBV subgenotype determination before treatment. Novel molecules described here could benefit future design/discovery of pan-D-subgenotypic inhibitors. IMPORTANCE Current treatment of chronic hepatitis B relies heavily on nucleotide/nucleoside analogs in particular, tenofovir disoproxil fumarate (TDF) and entecavir (ETV) to keep HBV replication under control and prevent end-stage liver diseases. However, it was unclear whether the therapeutic effects of TDF/ETV differ among patients infected with different HBV genotypes and subgenotypes. HBV genotype D is the most widespread of all HBV genotypes and multiple D-subgenotypes have been described. We here report that different subgenotypes of HBV genotype-D exhibit variable response toward TDF and ETV and this could be attributed to naturally occurring amino acid changes in the reverse transcriptase domain of the subgenotype-specific polymerase. Further, we identified novel molecules and also synthesized prodrugs that are equally effective on different D-subgenotypes and could facilitate management of HBV/D-infected patients irrespective of D-subgenotype." @default.
• W4225510445 created "2022-05-05" @default.
• W4225510445 creator A5000847224 @default.
• W4225510445 creator A5002942257 @default.
• W4225510445 creator A5007561625 @default.
• W4225510445 creator A5009286694 @default.
• W4225510445 creator A5017839481 @default.
• W4225510445 creator A5026188443 @default.
• W4225510445 creator A5027606308 @default.
• W4225510445 creator A5043737563 @default.
• W4225510445 creator A5061689047 @default.
• W4225510445 creator A5068947533 @default.
• W4225510445 creator A5070904348 @default.
• W4225510445 creator A5072171698 @default.
• W4225510445 creator A5080059638 @default.
• W4225510445 date "2021-11-03" @default.
• W4225510445 modified "2023-10-02" @default.
• W4225510445 title "Variability in the response of HBV D-subgenotypes to antiviral therapy: designing pan D-subgenotypic reverse transcriptase inhibitors" @default.
• W4225510445 cites W1607931568 @default.
• W4225510445 cites W192927429 @default.
• W4225510445 cites W1966739154 @default.
• W4225510445 cites W1973711348 @default.
• W4225510445 cites W1989228404 @default.
• W4225510445 cites W2013262494 @default.
• W4225510445 cites W2040958073 @default.
• W4225510445 cites W2050456292 @default.
• W4225510445 cites W2070933534 @default.
• W4225510445 cites W2074986801 @default.
• W4225510445 cites W2081595602 @default.
• W4225510445 cites W2099807267 @default.
• W4225510445 cites W2102993309 @default.
• W4225510445 cites W2127803531 @default.
• W4225510445 cites W2134970942 @default.
• W4225510445 cites W2137620760 @default.
• W4225510445 cites W2150569521 @default.
• W4225510445 cites W2155751613 @default.
• W4225510445 cites W2156552801 @default.
• W4225510445 cites W2158721163 @default.
• W4225510445 cites W2162705413 @default.
• W4225510445 cites W2177317049 @default.
• W4225510445 cites W2261335360 @default.
• W4225510445 cites W2277092291 @default.
• W4225510445 cites W2402419524 @default.
• W4225510445 cites W2597127774 @default.
• W4225510445 cites W2605666711 @default.
• W4225510445 cites W2767891136 @default.
• W4225510445 cites W2806143862 @default.
• W4225510445 cites W2893741441 @default.
• W4225510445 cites W3004011229 @default.
• W4225510445 cites W3005945360 @default.
• W4225510445 cites W3016298779 @default.
• W4225510445 cites W3029896968 @default.
• W4225510445 cites W4211196614 @default.
• W4225510445 doi "https://doi.org/10.1128/jvi.01800-21" @default.
• W4225510445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34730399" @default.
• W4225510445 hasPublicationYear "2021" @default.
• W4225510445 type Work @default.
• W4225510445 citedByCount "1" @default.
• W4225510445 countsByYear W42255104452023 @default.
• W4225510445 crossrefType "journal-article" @default.
• W4225510445 hasAuthorship W4225510445A5000847224 @default.
• W4225510445 hasAuthorship W4225510445A5002942257 @default.
• W4225510445 hasAuthorship W4225510445A5007561625 @default.
• W4225510445 hasAuthorship W4225510445A5009286694 @default.
• W4225510445 hasAuthorship W4225510445A5017839481 @default.
• W4225510445 hasAuthorship W4225510445A5026188443 @default.
• W4225510445 hasAuthorship W4225510445A5027606308 @default.
• W4225510445 hasAuthorship W4225510445A5043737563 @default.
• W4225510445 hasAuthorship W4225510445A5061689047 @default.
• W4225510445 hasAuthorship W4225510445A5068947533 @default.
• W4225510445 hasAuthorship W4225510445A5070904348 @default.
• W4225510445 hasAuthorship W4225510445A5072171698 @default.
• W4225510445 hasAuthorship W4225510445A5080059638 @default.
• W4225510445 hasBestOaLocation W42255104452 @default.
• W4225510445 hasConcept C104317684 @default.
• W4225510445 hasConcept C108215921 @default.
• W4225510445 hasConcept C153911025 @default.
• W4225510445 hasConcept C156719811 @default.
• W4225510445 hasConcept C159047783 @default.
• W4225510445 hasConcept C2522874641 @default.
• W4225510445 hasConcept C2776175608 @default.
• W4225510445 hasConcept C2777869810 @default.
• W4225510445 hasConcept C2779344132 @default.
• W4225510445 hasConcept C2780593183 @default.
• W4225510445 hasConcept C3013748606 @default.
• W4225510445 hasConcept C49105822 @default.
• W4225510445 hasConcept C54355233 @default.
• W4225510445 hasConcept C86803240 @default.
• W4225510445 hasConcept C98274493 @default.
• W4225510445 hasConceptScore W4225510445C104317684 @default.
• W4225510445 hasConceptScore W4225510445C108215921 @default.
• W4225510445 hasConceptScore W4225510445C153911025 @default.
• W4225510445 hasConceptScore W4225510445C156719811 @default.
• W4225510445 hasConceptScore W4225510445C159047783 @default.
• W4225510445 hasConceptScore W4225510445C2522874641 @default.
• W4225510445 hasConceptScore W4225510445C2776175608 @default.
• W4225510445 hasConceptScore W4225510445C2777869810 @default.
• W4225510445 hasConceptScore W4225510445C2779344132 @default.
• W4225510445 hasConceptScore W4225510445C2780593183 @default.
• W4225510445 hasConceptScore W4225510445C3013748606 @default.

• next